ScreenerNewsCompareWatchlist
VCP Scanner
ScreenerTechnicalBreakoutsThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistPricing
ScreenerTechnical ScannerBreakoutsThemes
Earnings
WatchlistPricing
Ctrl K
YDES
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
YDESYD Bio Limited Ordinary Shares
$2.24$9M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
YDES logo

YD Bio Limited Ordinary Shares

YDES
NASDAQ · Biotechnology
$2.24
At close - Jul 25, 4:00 PM EDT - USD
Market Cap$9M
P/E-4.0x
52W High$25.00
Volume82.45K
VCP VERDICT

Pre-Revenue Diagnostic Development Faces Critical Liquidity

YD Bio Limited remains in a high-risk, pre-commercial phase characterized by a complete lack of revenue and persistent operating losses. The company's financial stability is severe...

GrowthMixed
ProfitabilityNegative
ValuationFair
TechnicalsWeak
How this verdict is calculated

YDES Price & Volume

Loading chart...

What matters now

01

Earnings momentum

No recent earnings data

02

Valuation risk

P/E is 172% below its peer median

03

Market leadership

Laggard (Underperforming 97% of market)

04

Weak Trend

Price < 200DMA

Next catalyst

Next earnings unconfirmed

Performance Overview

Price History →

Trailing total returns as of 7/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
YDES-81.33%
S&P 500 (^GSPC)+8.16%
1-Year Return
YDES-81.40%
S&P 500 (^GSPC)+15.98%
3-Year Return
YDES-81.40%
S&P 500 (^GSPC)+55.50%
5-Year Return
YDES-81.40%
S&P 500 (^GSPC)+58.44%

Growth & profitability

Annual revenue & EPS trend
Revenue
$510K+45.8% YoY
Net income
-$1M-10509.7% YoY
Free cash flow
-$5M-8386.3% YoY
Operating margin
-286.5%-283.6 pts YoY
ROIC (TTM)-63.3%
Avg ROIC 5Y-
ROE (TTM)-42.7%
Piotroski Score3 / 9
Financial Statements →

Latest YDES News

Recent stock market news and headlines for YD Bio Limited Ordinary Shares (YDES)

GlobeNewsWire·Jul 2, 2026
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation (“EG BioMed US”), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company's transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.

Globe News Wire·Jul 2, 2026
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc. , a Delaware corporation ("EG BioMed US"), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company's transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.

Peers Comparison

Key metrics vs top competitors for YD Bio Limited Ordinary Shares (YDES)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
YDES logoYDESYD Bio Limited Ordinary SharesCurrent
$2.24$9.29M-4.0045.76%-276.58%-42.69%—
BTBT logoBTBTBit Digital, Inc.
$1.37$446.13M-4.42-30.65%-146.01%-0.11%—
NUVB logoNUVBNuvation Bio Inc.
$6.42$2.23B-10.70698.96%-102.06%-44.1%—
ZLAB logoZLABZai Lab Limited
$19.22$2.13B-12.0115.33%-39.29%-24.32%—
ZYME logoZYMEZymeworks Inc.
$22.86$1.68B-21.1738.87%-126.33%-0.25%—
IQ logoIQiQIYI, Inc.
$1.22$1.18B-39.34-6.62%-0.77%-0.22%—

Compare YDES vs Peers

YD Bio Limited Ordinary Shares (YDES) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BTBT

Most directly comparable listed peer for YDES.

Scale Benchmark

vs IMVT

Larger-name benchmark to compare YDES against a more recognizable public peer.

Peer Set

Compare Top 5

vs BTBT, NUVB, ZLAB, ZYME

Get notified when YDES posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

YDES Frequently Asked Questions

YD Bio Limited Ordinary Shares (YDES) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is YD Bio Limited Ordinary Shares's revenue?

YD Bio Limited Ordinary Shares (YDES) reported $0.5M in revenue for fiscal year 2024.

How fast is YD Bio Limited Ordinary Shares growing?

YD Bio Limited Ordinary Shares (YDES) grew revenue by 45.8% over the past year. This is strong growth.

Is YDES profitable?

YD Bio Limited Ordinary Shares (YDES) reported a net loss of $3.0M for fiscal year 2024.

Dividend & Returns
What is YDES's return on equity?

YD Bio Limited Ordinary Shares (YDES) has a return on equity (ROE) of -42.7%. Negative ROE indicates the company is unprofitable.

What is YD Bio Limited Ordinary Shares's free cash flow?

YD Bio Limited Ordinary Shares (YDES) had negative free cash flow of $1.2M in fiscal year 2024, likely due to heavy capital investments.

What if you invested $1,000 in YDES back in 2020?

Total return calculator · dividends reinvested · 6+ years of data

See returns →